AtheroGenics, Inc.{AGIX}-nasdaq Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: idos	4/14/2008 9:04:15 AM
	of 332

AtheroGenics drug shows promise in lowering sugar level reuters.com Mon Apr 14, 2008 8:49am EDT (Corrects typo in company name in headline) (Adds background, details, share movement) April 14 (Reuters) - AtheroGenics Inc (AGIX.O: Quote, Profile, Research) said an interim analysis of a late-stage study of its failed heart-drug, AGI-1067, showed a reduction in blood sugar levels in patients with diabetes. The ongoing Phase 3 trial, named ANDES, is evaluating two doses of AGI-1067 - 75 mg and 150 mg - given once daily over six months to patients with Type 2 diabetes. The main goal is an improvement in A1c, a key blood sugar measure, at six months compared with a dummy drug. The interim analysis of 806 patients showed dose-related statistically significant reductions in A1c after three months of dosing. A total of 999 patients were enrolled in the trial, the company said. AtheroGenics had discontinued a 300 mg dose of the drug in the ANDES trial on concerns about adverse effects on the liver as seen in the ARISE trial where AG-1067 had failed as an experimental heart drug. Shares of the company were at $1 in trading before the bell after closing at 84 cents Friday on Nasdaq. The shares have lost nearly three-fourths their value in the last one year. (Reporting by Niveditha Ravi in Bangalore; Editing by Jarshad Kakkrakandy)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next